Results 171 to 180 of about 338,443 (309)
Deep docking, part 2: an amplified DDU platform for ultra-large virtual screening. [PDF]
Pandey M +7 more
europepmc +1 more source
CTBPro is a next‐generation cholera toxin B–based tracer engineered by fusing CTB to the ultra‐stable fluorescent protein mBaojin. Exhibiting markedly enhanced molar brightness, CTBPro enables high‐fidelity neuronal labeling across multiple administration routes.
Xinghua Quan +12 more
wiley +1 more source
Comparative Evaluation of Explicit Solvent Models for RNA-Ligand Docking. [PDF]
Almena Rodriguez L, Kersten C.
europepmc +1 more source
This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma +10 more
wiley +1 more source
This study identifies S100A14 in tumor‐derived exosomes as a key driver of brain metastasis. S100A14 targets PIAS3 in astrocytes, activating STAT3 signaling and promoting immunosuppressive MDSCs recruitment via chemokine secretion. Germacrone, a natural compound, binds S100A14 to disrupt this axis, effectively inhibiting brain metastasis with low ...
Qian Feng +13 more
wiley +1 more source
A NAMs-based framework for screening the endocrine-disrupting potential of plastic additives using cross-species molecular docking and <i>Caenorhabditis elegans</i>. [PDF]
Chong C, Kim D, Kang K, Choi J.
europepmc +1 more source
ANKS1B in the nucleus accumbens plays a critical role in the transition from controlled to escalated cocaine intake. Mechanistically, ANKS1B interacts with CBP to epigenetically suppress FoxO3 through H3K27 acetylation. The ANKS1B‐CBP‐FoxO3 signaling cascade presents a novel theraputic target for the treatment of cocaine addiction.
Liping Yang +15 more
wiley +1 more source
Real-world bleeding risk and molecular interaction profiles of direct oral anticoagulants: a comparative study integrating clinical outcomes and <i>in silico</i> docking. [PDF]
Onar LC, Guner E, Yilmaz I.
europepmc +1 more source
MDM2 dependency in pediatric sarcomas is driven by a novel p53‐independent oncogenic cistrome alongside canonical p53 pathway suppression. This study introduces MDM2‐recruiting transcriptional and epigenetic machinery degraders (MDM2‐TEMADs) as a novel precision oncology modality.
Jiawei Zhou +21 more
wiley +1 more source

